Latebreakers: September 4, 2006

Researchers assessed the difference between hidradenitis suppurativa and other skin conditions regarding the initiating events, inflammatory signature, and molecular and clinical features of each disease.

With federal reform continuing to stall, Drug Topics caught up with Iowa State Representative Brett Barker, PharmD, to discuss how his state is regulating pharmacy benefit managers.

Researchers conducted a retrospective cohort study to understand pneumococcal disease patterns, vaccine coverage, and the overall burden of the disease on adults in France.

In this episode, Natalie DiPietro Mager, PharmD, PhD, speaks with Lindsay Ferraro, PharmD, associate professor of pharmacy practice at Ohio Northern University.

The approval is based on the FINEARTS-HF (NCT04435626), showing that the drug achieved a 16% relative risk reduction of cardiovascular death and total heart failure events.

Michael Kleinrock from IQVIA joined Drug Topics to discuss his company’s recently released report, Understanding the Use of Medicines in the US 2025.